Idiopathic Pulmonary Fibrosis Market Report 2026

Idiopathic Pulmonary Fibrosis Market Overview

• Idiopathic Pulmonary Fibrosis market size has reached to $4.37 billion in 2025 • Expected to grow to $6.16 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Growing Geriatric Population Fuels Expansion Of Idiopathic Pulmonary Fibrosis Market • Market Trend: Groundbreaking Anti-Fibrotic Small-Molecule Inhibitor Paving The Way In Idiopathic Pulmonary Fibrosis Treatment • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Idiopathic Pulmonary Fibrosis Market?

Idiopathic pulmonary fibrosis (IPF) is a lung disease characterized by the gradual and continuous deterioration of the tissue encompassing the air sacs, known as alveoli, in the lungs. This condition leads to the accumulation of scar tissue (fibrosis) within the lungs, impeding the efficient transportation of oxygen into the bloodstream. The main drug types in idiopathic pulmonary fibrosis include nintedanib, pirfenidone, and others. Nintedanib is a medication prescribed for the treatment of specific lung conditions, such as idiopathic pulmonary fibrosis (IPF), an interstitial lung disease with a progressive phenotype, and interstitial lung disease associated with systemic sclerosis. The various modes of action include antifibrotic agents, tyrosine kinase inhibitors, and others with various routes of administration such as oral and parenteral. The various distribution channels include hospital pharmacies, retail pharmacies, and online for the various end users, including hospitals, clinics, and others.

What Is The Idiopathic Pulmonary Fibrosis Market Growth Forecast?

The idiopathic pulmonary fibrosis market size is expected to see strong growth in the next few years. It will grow to $6.16 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growing research investment in pulmonary fibrosis, development of next-generation antifibrotic drugs, increasing use of real-world evidence in treatment decisions, expansion of online and specialty pharmacy channels, rising awareness of rare respiratory diseases. Major trends in the forecast period include increasing adoption of antifibrotic therapies, rising focus on early and accurate diagnosis, growing use of combination drug therapies, expansion of home-based and long-term disease management, increasing participation in clinical trials for novel therapies.

What Is The Driver Of The Idiopathic Pulmonary Fibrosis Market?

An increasing geriatric population is expected to boost the growth of the idiopathic pulmonary fibrosis market going forward. The geriatric population refers to the elderly or senior citizens within a given society or population. Aging is associated with structural and functional changes in the lungs, making older individuals more susceptible to respiratory diseases such as IPF. This age-related vulnerability contributes to the overall demand for IPF treatments. For instance, in January 2024, according to the Population Reference Bureau, a US-based non-profit organization, reported that the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. As a result, this age group’s proportion of the total U.S. population will grow from 17% to 23% during this period. Therefore, the increasing geriatric population is driving the growth of the idiopathic pulmonary fibrosis industry.

Key Players In The Global Idiopathic Pulmonary Fibrosis Market

Major companies operating in the idiopathic pulmonary fibrosis market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

Global Idiopathic Pulmonary Fibrosis Market Trends and Insights

Major companies operating in the idiopathic pulmonary fibrosis (IPF) market are focusing on innovative products, such as anti-fibrotic small-molecule inhibitors, to sustain their position in the market. Anti-fibrotic small-molecule inhibitors refer to a type of pharmaceutical compound designed to target and inhibit the fibrotic processes in the body. For instance, in June 2023, Insilico Medicine, a US-based clinical-stage biotechnology company using generative artificial intelligence (AI), announced the initiation of Phase II clinical trials for INS018_055, the world’s first anti-fibrotic small molecule inhibitor designed through generative AI. This milestone marks the first dose administered to patients in the trial, which is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of a 12-week oral dosage of INS018_055 in subjects with idiopathic pulmonary fibrosis (IPF). This innovative approach leverages AI in drug discovery, showcasing a potential advancement in the treatment of idiopathic pulmonary fibrosis (IPF) diseases.

What Are Latest Mergers And Acquisitions In The Idiopathic Pulmonary Fibrosis Market?

In October 2023, Aileron Therapeutics, a US-based biopharmaceutical company, acquired Lung Therapeutics Inc. for an undisclosed amount. With this acquisition, Aileron aimed to bolster its therapeutic pipeline by gaining the clinical-stage IPF asset LTI-03, thereby accelerating development in idiopathic pulmonary fibrosis. Lung Therapeutics is a US-based biopharmaceutical company focused on developing novel peptide-based therapies like LTI-03, a Caveolin-1–related peptide for orphan pulmonary fibrosis indications including IPF.

What Defines the Idiopathic Pulmonary Fibrosis Market?

The idiopathic pulmonary fibrosis (IPF) market consists of sales of anti-inflammatory, MAPK inhibitors, autotoxin inhibitors and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Idiopathic Pulmonary Fibrosis Market Report 2026?

The idiopathic pulmonary fibrosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the idiopathic pulmonary fibrosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.